Cancer immunotherapy, particularly CAR-T cells, has transformed the landscape of cancer treatment, offering a paradigm shift in prognosis. To enhance the efficacy of cancer treatment, recent scientific endeavors have concentrated on harnessing the potential of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-associated protein 9 (Cas9) technology where they use this technology to cancer treatments and cancer immunotherapy including the engineered CAR-T cell. There have been a lot of advances including correcting genetic mutation, curing genetic disorders, etc. this review paper will cover cancer immunotherapy, CAR-T cell therapy and it;s mechanism, successful clinical trials, ongoing clinical trials, the current limitations as well as the future advantages of this technology.
No takes yet. Share an insight, caveat, or question.
Farrokhi et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: